IL270388B2 - A method for treating ischemic tissue - Google Patents

A method for treating ischemic tissue

Info

Publication number
IL270388B2
IL270388B2 IL270388A IL27038819A IL270388B2 IL 270388 B2 IL270388 B2 IL 270388B2 IL 270388 A IL270388 A IL 270388A IL 27038819 A IL27038819 A IL 27038819A IL 270388 B2 IL270388 B2 IL 270388B2
Authority
IL
Israel
Prior art keywords
aav
selectin
subject
aav2
sequence encoding
Prior art date
Application number
IL270388A
Other languages
English (en)
Hebrew (he)
Other versions
IL270388B1 (en
IL270388A (cg-RX-API-DMAC7.html
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of IL270388A publication Critical patent/IL270388A/en
Publication of IL270388B1 publication Critical patent/IL270388B1/en
Publication of IL270388B2 publication Critical patent/IL270388B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
IL270388A 2017-05-02 2018-05-02 A method for treating ischemic tissue IL270388B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500470P 2017-05-02 2017-05-02
PCT/US2018/030615 WO2018204475A1 (en) 2017-05-02 2018-05-02 Method for treating ischemic tissue

Publications (3)

Publication Number Publication Date
IL270388A IL270388A (cg-RX-API-DMAC7.html) 2019-12-31
IL270388B1 IL270388B1 (en) 2023-11-01
IL270388B2 true IL270388B2 (en) 2024-03-01

Family

ID=64016314

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270388A IL270388B2 (en) 2017-05-02 2018-05-02 A method for treating ischemic tissue

Country Status (9)

Country Link
US (1) US20200062820A1 (cg-RX-API-DMAC7.html)
EP (1) EP3618852A4 (cg-RX-API-DMAC7.html)
JP (1) JP7450244B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200013674A (cg-RX-API-DMAC7.html)
CN (1) CN110769861A (cg-RX-API-DMAC7.html)
AU (1) AU2018261420A1 (cg-RX-API-DMAC7.html)
CA (1) CA3097135A1 (cg-RX-API-DMAC7.html)
IL (1) IL270388B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018204475A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102545491B1 (ko) * 2020-08-13 2023-06-21 동국대학교 산학협력단 신규한 뇌혈관질환 동물모델 제조방법 및 이에 의해 제조된 뇌혈관질환 동물모델을 이용하여 뇌혈관질환 발병 감수성 개체 차이가 작은 동물을 생산하기 위한 방법
US20240237960A1 (en) * 2021-06-11 2024-07-18 Jubilant Draximage Inc. Expert scoring system for measurement of severity, treatment response and prognosis of peripheral arterial disease
EP4694905A1 (en) * 2023-04-13 2026-02-18 University of Miami Method for promoting myogenesis and skeletal muscle recovery
CN121570599B (zh) * 2026-01-27 2026-05-15 中山大学中山眼科中心 Sele在湿性年龄相关性黄斑变性治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058086A1 (en) * 2009-04-21 2012-03-08 Velazquez Omaida C Compositions, kits, and methods for promoting ischemic and diabetic wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016761A2 (en) * 2002-08-16 2004-02-26 Schering Aktiengesellschaft Gene therapy for critical limb ischemia with wild type or mutant enos
WO2011053896A2 (en) * 2009-10-30 2011-05-05 University Of Miami Hypoxia regulated conditionally silenced aav expressing angiogenic inducers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058086A1 (en) * 2009-04-21 2012-03-08 Velazquez Omaida C Compositions, kits, and methods for promoting ischemic and diabetic wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HORKAN DAVIS B ET AL:, PC224. INCREASING E-SELECTIN BY RECOMBINANT ADENOASSOCIATED VIRUS IMPROVES ANGIOGENESIS IN A MURINE MODEL OF HIND LIMB ISCHEMIA, 1 June 2015 (2015-06-01) *
TAEYOUNG KOO ET AL:, DELIVERY OF AAV2/9-MICRODYSTROPHIN GENES INCORPORATING HELIX 1 OF THE COILED-COIL MOTIF IN THE C-TERMINAL DOMAIN OF DYSTROPHIN IMPROVES MUSCLE PATHOLOGY AND RESTORES THE LEVEL OF [ALPHA]1-SYNTROPHIN AND [ALPHA]-DYSTROBREVIN IN SKELETAL MUSCLES OF MDX, 1 November 2011 (2011-11-01) *
ZHAO-JUN LIU:, 603. SDF-L-ALPHA-ENGINEERED CELL-BASED THERAPY FORDIABETIC WOUND HEALING, 1 May 2010 (2010-05-01) *

Also Published As

Publication number Publication date
IL270388B1 (en) 2023-11-01
JP7450244B2 (ja) 2024-03-15
US20200062820A1 (en) 2020-02-27
EP3618852A1 (en) 2020-03-11
KR20200013674A (ko) 2020-02-07
WO2018204475A1 (en) 2018-11-08
JP2020518644A (ja) 2020-06-25
EP3618852A4 (en) 2021-01-06
CA3097135A1 (en) 2018-11-08
CN110769861A (zh) 2020-02-07
IL270388A (cg-RX-API-DMAC7.html) 2019-12-31
AU2018261420A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
Johnson et al. Approaches to therapeutic angiogenesis for ischemic heart disease
TWI775096B (zh) 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
Li et al. Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model
IL270388B1 (en) Method for treating ischemic tissue
IL262262B2 (en) Adeno-associated virus vector delivery of B-sarcoglycan and microRNA-29 and treatment of muscular dystrophy
Atluri et al. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential
IL258005B1 (en) Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
Wang et al. Advancements in gene-based therapeutic angiogenesis for chronic limb-threatening ischemia
Fujita et al. Therapeutic angiogenesis using autologous CD34-positive cells for vascular diseases
CN102755638A (zh) Aggf1在制备促进血管形成的药物中的用途
JP2012524781A (ja) 虚血性及び糖尿病性創傷の治癒を促進する組成物、キット及び方法
LEK Genetically engineered mesenchymal stem cells using viral vectors: A new frontier in Anti-Angiogenic therapy
KR20190050277A (ko) 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물
CN112516168B (zh) 用于干预应激性认知障碍的间充质干细胞
Duscha et al. Angiogenesis in peripheral artery disease: an emerging therapy targeting skeletal muscle
Ignaczak et al. From Adipose Tissue to Cardiac Repair: Extracellular Vesicles in Cardiovascular Regeneration
Afzal et al. Hematopoietic stem cell‑based angiotensin‑(1‑7) delivery to the brain improves functional outcome following cerebral ischemia
WO2025193755A1 (en) Methods and compositions for treatment of hydrocephalus
Gruntman A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies
Liu Ultrasound-guided transgene expression of KLK10 to inhibit atherosclerosis
VandenDriessche et al. 24. Widespread and Efficient Gene Delivery to the Heart and Liver Using AAV Serotype 9: Implications for Cardiovascular Disease and Hemophilia
WO2024216156A1 (en) Method for promoting myogenesis and skeletal muscle recovery
Boden Femoral artery regeneration in ischemic hind limb by AAV9 expressing conditionally silenced VEGF
Puligadda In vivo evaluation of the cardioprotective activity of VEGF-B